Objective: Cannabis is the most commonly used illicit substance in the United States and is increasingly being legalized throughout the United States. Many believe that cannabis is relatively harmless, and some believe that cannabis is not addictive. We wondered what the rates of cannabis abuse and dependence might be among adolescents referred for substance use evaluations and also about the incidence of co-occurring psychiatric illnesses and substance use disorders among those individuals.
I
n recent years, cannabis has remained the most commonly used illicit substance in the United States, with 80.6% of illicit substance users reporting using in the last year (Substance Abuse and Mental Health Services, 2014) . This occurs in the setting of considerable national debate surrounding the legalization of marijuana, with several states recently passing measures to legalize cannabis for recreational or medical use.
Legalization of cannabis has raised concerns regarding the potential effects on use among adolescents. Rates of cannabis use have steadily increased among adolescents since 2008, with surveys indicating current use in up to 20.6% of 12th-grade students (Kuehn, 2011 ; Institute for Social Research, 2012) . Data also show that these increases are accompanied by a softening of adolescent attitudes about the risks of cannabis use (Substance Abuse and Mental Health Services, 2014; Kuehn, 2013) . These findings have serious implications for mental health and functioning, as adolescent cannabis use is associated with increased rates of later depression, psychotic illness and suicidal behavior (Rey et al., 2004; Rubino et al., 2012) , and poor educational attainment and the use of other illicit substances (Macleod et al., 2004) .
To our knowledge, no studies to date have rigorously examined the incidence of co-occurring psychiatric illnesses and substance use disorders among a large cohort of adolescent cannabis users in the outpatient setting. Existing studies have primarily investigated inpatients or incarcerated youths (Wilens et al., 1997) or have assessed psychiatric symptoms rather than diagnoses (Modrzejewska, 2010) . Furthermore, most previous work has relied on information gleaned from adolescent patients, who may underreport psychiatric symptoms or substance use (Turner et al., 1998) .
The Adolescent Substance Abuse Program (ASAP) at Boston Children's Hospital has an extensive evaluation process in which the adolescent patients are examined and, at the same time, their parent(s) or guardian(s) are interviewed separately in a series of meetings totaling 4 hours. After these meetings, the multidisciplinary staff meet to review all findings, arrive at the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) diagnoses, and make treatment recommendations. In our study, we examine a population of ASAP patients to determine overall prevalence of psychiatric comorbidities and the specific rates of co-occurring mood, anxiety, psychotic, and behavioral disorders among patients diagnosed with cannabis use disorders. As a secondary aim, we examine whether certain demographic factors increase the odds of having a cannabis use disorder.
METHODS
Our study proposal was reviewed and approved by the institutional review board at Boston Children's Hospital. As described above, ASAP staff met with both adolescent patients and their families before coming together to develop diagnoses and recommendations. At this juncture social work staff recorded all findings in the electronic medical record (EMR). The final step of the intake process occurred with the adolescents and their caregivers meeting together with an ASAP staff member to review findings and treatment recommendations. The ASAP EMR was queried to generate a list of 560 consecutive adolescents who scheduled initial appointments in ASAP from late 2009 through early 2013. Electronic medical record data collected included diagnoses, race/ethnicity, sex, age at time of evaluation, and zip code. Publicly available US census data on median household income by zip code provided a proxy estimate of subjects' household income. In 67 cases, data could not be obtained because the adolescent either never came in for an initial meeting or came in for an initial meeting but did not complete the full evaluation. Diagnostic information about individuals was obtained by reviewing diagnoses in both the social work logs and EMR notes. In total, we were able to retrieve diagnostic and demographic data on 483 patients.
If a diagnosis of "rule out abuse" of a substance was recorded in the chart, we coded this as "problem use" of that substance. Although "problem use" is not a diagnosis found in the Diagnostic and Statistical Manual of Mental Disorders, the ASAP team would render this finding if the use of a substance was causing problems in the individual's life that did not rise to the level of a diagnostic problem. Analogously, if a diagnosis of "rule out dependence" was recorded we coded this as "substance abuse" rather than "substance dependence." Rule out psychiatric and problem use diagnoses were excluded from analysis.
Odds ratios and percentages were calculated using Excel and R programming software to determine associations of cannabis use with other diagnoses and with socioeconomic factors. For these stratifications, the reference group consisted of patients without a cannabis disorder, but who may have had other substance use disorders.
RESULTS
Rates of cannabis abuse and dependence in our sample were high. Out of 483 individuals whose records we reviewed, 232 (48%) were found to be cannabis dependent, 159 (32.9%) were found to meet criteria for cannabis abuse, and another 21 (4.4%) were found to have problem use of cannabis (Table 1) . Thus, 412 (85.3%) of our subjects were found to have either cannabis dependence, abuse, or problematic use. The mean age of our sample was 16.9 years (SD = 1.89), with a range of 11 to 24 years. Most patients were male (67.9% male; 32.1% female), and white (59.4% white; 6.4% black; 6.8% Hispanic/Latino; 1.9% Asian; 2.7% other). Race was missing for 22.8% of our sample. The average median income by zip code was $90,186.63 (SD = 34,303.12), with a range of $26,552 to $201,065. Those with a cannabis abuse or dependence diagnosis were more likely to be male compared with those with no cannabis use disorder.
Nearly all patients in our sample met diagnostic criteria (according to the Diagnostic and Statistical Manual of Mental Disorders [Fourth Edition, Text Revision] ) for a substance use disorder (97.9%), and 9.3% of our sample met criteria for polysubstance dependence, defined as concurrent dependence on 3 or more substances with the exception of nicotine ( Table 2) . The most common substance use disorders found in our sample were cannabis dependence and abuse as noted above, alcohol abuse (38.9%), alcohol dependence (19.9%), alcohol problem use (8.7%), and opioid dependence (22.2%). Significant minorities of patients also met diagnostic criteria for cocaine dependence (5.2%), cocaine abuse (4.2%), and cannabis problem use (4.4%). Those with cannabis dependence were also more likely to suffer from a co-occurring Axis I psychiatric diagnosis compared with those with no cannabis use disorder. Indeed, these patients were also more likely to suffer from 2 or more psychiatric disorders. Patients with cannabis abuse or dependence were also twice as likely to be diagnosed with attentiondeficit/hyperactivity disorder (ADHD) compared with patients with no cannabis use disorder. Cannabis users were more likely to meet criteria for alcohol abuse and dependence and more likely to meet the criteria for polysubstance dependence compared with those with no cannabis use disorder.
DISCUSSION
Co-occurrence of substance-related and other mental health disorders is the rule, not the exception, among adolescent cannabis users in the outpatient setting. Consistent with previous studies, we found a high rate of co-occurrence between a primary cannabis use disorder and other Axis I psychiatric diagnoses. We also found a high degree of polysubstance use, abuse, and dependence.
The rates of both cannabis abuse (32.9% of our population) and dependence (48%) were high in our population. This is of particular concern given the known contribution of cannabis to cognitive and functional impairments in adolescents, whose neurodevelopment may be significantly impacted by cannabis use. In particular, adolescents who use cannabis daily have been shown to suffer deficits in learning up to 6 weeks after cannabis cessation. (Sheinsburg et al., 2008) . Cannabis use is also associated with decreased academic achievement, increased rates of school dropout, and failure to achieve in higher education (Fergusson et al., 2003) . Counseling for both adolescents and their families regarding these risks may prove a crucial part of prevention or cessation.
Previous research has shown that the majority of adolescents diagnosed with cannabis dependence suffer from at least 2 other Axis I diagnoses (Norberg et al., 2013) , and our results support this finding. Those with cannabis dependence were not only more likely to suffer from a co-occurring nonsubstance-related Axis I diagnosis, but also more likely to be diagnosed with more than 1 such disorder. This again indicates the need for careful screening for other mental illness among these adolescents and monitoring of the impact of cannabis use on the progression of these illness because cannabis use has also been associated with the emergence and increased severity of several mood, anxiety, and psychotic disorders in adolescents (McGrath et al., 2010; Degenhardt et al., 2013) .
Notably, patients with cannabis abuse or dependence were twice as likely to be diagnosed with ADHD (Table 2 ). This suggests that careful screening for ADHD among cannabis users may prove clinically important, particularly as their substance use may affect the decision to treat with controlled substances such as amphetamines. Given recent increases in diagnoses of ADHD and controversies surrounding the risks/benefits of treatment, including the potential risk for addiction to stimulants, this may prove an important clinical consideration (Degenhardt et al., 2013) . In our cohort, those with a cannabis abuse or dependence diagnosis were more likely to be male, suggesting that male patients may be at increased risk for cannabis use disorders.
Adolescents with cannabis abuse or dependence were more likely to meet criteria for alcohol abuse than those with no cannabis use disorder. The combination of cannabis and alcohol use raises particular safety concerns, as cannabis impairs driving in a dose-dependent manner by affecting the automatic behaviors (acceleration, braking, etc) associated with driving (Sewell et al., 2009 ). In combination with alcohol, cannabis use greatly increases the risk of motor vehicle accidents due to its additive effects on cognition and coordination (Ramaekers et al., 2004) . Therefore, patients with cannabis use may benefit not only from alcohol abuse screening, but also from counseling regarding safe and responsible driving. Finally, those with cannabis dependence were far more likely to meet criteria for polysubstance dependence than those with no cannabis use disorder. This may occur because these adolescents already met dependence criteria for 1 of 3 required substances (ie, cannabis). However, the findings suggest the need to screen for other substance use disorders beyond alcohol abuse.
Our data suggest that patients of all 3 age groups (<16 years old, 16-17 years of age, and >18 years old) were equally likely to be diagnosed with cannabis dependence. This underscores the importance of screening for symptoms of cannabis dependence regardless of age and counseling patients/families on appropriate management, including the management of potential physiologic and emotional effects of withdrawal. Interestingly, older patients (>18 years old) were less likely to be diagnosed with cannabis problem use or abuse compared with younger patients, possibly suggesting that by this later age most cannabis users have advanced to the more severe category of dependency. This again suggests the importance of early screening, which is particularly relevant given research showing the effectiveness of targeted intervention for younger adolescents, involving multiple facilitators, and with implementation of booster sessions (Norberg et al., 2013) . Recent research indicates the effectiveness of school-based, personality-targeted interventions (Conrod et al., 2013) , suggesting that early interventions should expand beyond the physician's office to include other venues relevant to the adolescent. Our data also suggest that household income does not significantly influence likelihood of any cannabis use disorder, perhaps due to easy or affordable access, and therefore further supports the need for universal screening.
Because of practical limitations, a comprehensive and thorough psychiatric screening may not prove possible for every adolescent with a cannabis use disorder presenting to a primary care or pediatric office. In such cases, patients may benefit from appropriate referrals. Primary care providers, after consultation, may be better able to address the impact of co-occurring disorders with patients and their parents/families and tailor interventions to each case. From a policy standpoint, given the trend toward decriminalization of cannabis in several states, lawmakers and professionals alike should consider the impact of increased adolescent cannabis use on psychiatric *Unable to calculate due to small n. †Data are given as odds ratios (ORs) (95% confidence intervals). The ORs represent the odds of having a certain demographic characteristic or comorbid psychiatric or substance use disorder among individuals with cannabis use disorders. The reference group is ASAP patients without a cannabis use disorder so no ORs are presented for this group. ADHD, attention-deficit/hyperactivity disorder; GAD, generalized anxiety disorder; NOS, not otherwise specified; OCD, obsessive-compulsive disorder; OR, odds ratio; PTSD, posttraumatic stress disorder.
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health, and risk of other co-occurring addictions, in their deliberations.
Several limitations to our study should be noted. Our study drew on a population of patients referred due to particular concerns of substance use, and therefore may suffer from higher rates or more acute forms of substance use compared with a more general outpatient population. We did not ascertain how long participants had used substances before coming in for their evaluation. However, a subset of our population (n = 170) was subjected to a more thorough chart review in a separate study and was found to have a mean onset of 2.5 years of substance use before coming to ASAP (S. Harris and J. Knight, unpublished data, written personal communication, 2013) . We have no reason to believe this subset differs from the total set of our patients in any appreciable way.
The strengths of our study include a relatively large sample size and the combination of an outpatient setting with a thorough evaluation of both substance use and psychiatric diagnoses among our adolescent patients. Future avenues of research may include the examination of co-occurring disorders among patients in more general outpatient pediatric and psychiatric settings and longitudinal follow-up to determine the efficacy of various interventions in treating these adolescent patients.
